Cost-effectiveness analysis of various screening methods for osteoporosis in perimenopausal Thai women

Gynecologic and Obstetric Investigation

Volumn 62, Issue 2, 2006, Pages 89-96

  Panichkul, Suthee ^a   Panichkul, Prisana ^a   Sritara, Chanika ^b   Tamdee, Decha ^c  

^a PHRAMONGKUTKLAO HOSPITAL   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

^c CHIANG MAI UNIVERSITY   (Thailand)

Author keywords

Cost effective; Osteoporosis; Screening

Indexed keywords

CALCIUM;

ADULT; ARTICLE; BONE MASS; CLIMACTERIUM; CLINICAL EXAMINATION; COST EFFECTIVENESS ANALYSIS; DUAL ENERGY X RAY ABSORPTIOMETRY; ECHOGRAPHY; FEMALE; FRACTURE; HIP FRACTURE; HORMONE SUBSTITUTION; HUMAN; INTERMETHOD COMPARISON; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; QUANTITATIVE ULTRASOUND SONOGRAPHY; RISK FACTOR; RISK INDEX; SCREENING; SENSITIVITY AND SPECIFICITY; THAILAND; ULTRASOUND;

ABSORPTIOMETRY, PHOTON; BONE DENSITY CONSERVATION AGENTS; COST-BENEFIT ANALYSIS; DECISION TREES; DENSITOMETRY, X-RAY; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MASS SCREENING; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; THAILAND; ULTRASONOGRAPHY;

EID: 33746866785     PISSN: 03787346     EISSN: None     Source Type: Journal    
DOI: 10.1159/000092803     Document Type: Article

References (21)

1. Garraway WM, Stauffer RN, Kurland LT, O'Fallon WM: Limb fractures in a definite population. Orthopedic treatment and utilization of health care. Mayo Clin Proc 1975;54:708-713.
2. Kanis JA, Dawson A, Oden A, Johnell O, De Laet C, Jonsson B: Cost-effectiveness of preventing hip fracture in the general female population. Osteoporos Int 2001;12:356-361.
3. Tosteson AN, Weinstein MC: Cost-effectiveness of hormone replacement therapy after the menopause. Baillieres Clin Obstet Gynaecol 1991;5:943-959.
4. Tosteson AN, Rosenthal DI, Melton LJ III, Weinstein MC: Cost effectiveness of screening perimenopausal white women for osteoporosis: bone densitometry and hormone replacement therapy. Ann Intern Med 1990;113:594-603.
5. Limpaphayom K, Taechakraichana N, Jaisamrarn U: Prevalence of osteopenia and osteporosis in Thai women. Menopause 2001;8:65-69.
6. Kanis JA, Melton LJ III, Christiansen C: The diagnosis of osteoporosis. J Bone Miner Res 1994;9:1137-1141.
7. Hans D, Dargent-Molina P, Schott AM: Ultrasonographic heel measurements to predict hip fracture in elderly women: the EPIDOS prospective study. Lancet 1996;348:511-514.
8. Melton LJ, Wahner HW, Richelson LS: Osteoporosis and the risk of hip fracture. Am J Epidemiol 1986;124:254-261.
9. Cadarette SM, Jaglal SB, Murray TM: Evaluation of decision rules for referring women for bone densitometry by dual-energy x-ray absorptiometry. JAMA 2001;286:57-63.
10. Stewart A, Reid DM: Quantitative ultrasound or clinical risk factors which best identifies women at risk of osteoporosis. Br J Radiol 2000;73:165-171.
11. Ekman A, Michaelsson K, Petren MM, Ljunghall S, Mallmin H: DXA of the hip and heel ultrasound but not densitometry of the fingers can discriminate female hip fracture patients from controls: A comparison between four different methods. Osteoporos Int 2001;12:185-191.
12. Koh LK, Sedrine WB, Torralba TP: A simple tool to identify Asian women at increased risk of osteoporosis. Osteoporos Int 2001;12:699-705.
13. Mortensen L, Charles P, Bekker PJ, Digennaro J, Johnston CC: Resedronate increases bone mass in an elderly postmenopausal population: two years of treatment plus one year of follow-up. J Clin Endocrinol Metab 1998;83:396-402.
14. Grady D, Herrington D, Bittner V: Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002;288:49-57.
15. Hulley S, Furberg C, Barrett-Connor E, Cauley J, Grady D, Haskell W, et al: Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002;288:58-66.
16. Writing Group for the Women's Health Initiative Investigator: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results. From the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
17. Grady D: Postmenopausal hormones - therapy for symptoms only. N Engl J Med 2003;348:1835-1837.
18. Gold MR, Siegal JE, Russel LB: Cost-Effectiveness in Health and Medicine. Oxford University Press, 1996.
19. Dere W, Avouac B, Boers M: Recommendations for the health economics analysis to be performed with a drug to be registered in prevention or treatment of osteoporosis. Calcif Tissue Int 1998;63:93-97.
20. Lufkin EG, Whitaker MD, Nickelsen T: Treatment of established postmenopausal osteoporosis with raloxifene: a randomized trial. J Bone Miner Res 1998;13:1747-1754.
21. Stephen AB, Wallace WA: The management of osteoporosis. J Bone Joint Surg Br 2001;83:316-323.